Achieve Life Sciences to present 52-week cytisinicline efficacy data at CHEST 2026
The open-label ORCA-OL study includes 475 adults who previously participated in earlier cytisinicline studies and continued to smoke or vape daily.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. NASDAQ:ACHV, a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that ne…
Achieve Life Sciences to present 52-week cytisinicline data at CHEST 2026
Achieve Life Sciences said it will present 52-week cytisinicline efficacy data for smoking and e-cigarette cessation at CHEST 2026.